All News
The RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read Article
Offspring of RA Women Have Higher Risk of RA and Other Diseases
Despite a growing body of evidence suggesting that maternal health is more important than maternal medications to fetal and infant outcomes, little is known about the long term oucomes of infants born to mothers with rheumatoid arthritis (RA). Using Danish population data, researchers have shown in utero exposure to maternal RA is associated with an increased risk of thyroid disease, and an increased risk of future RA.
Read Article
The RheumNow Week in Review - 8 December 2017
Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.
Read Article
Pregnancy Outcomes Worse with Myopathies
Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.
Read Article
The ACR17 RheumNow Week in Review - 10 November 2017
This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr.
Read Article
My ACR Takeaways
With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice.
ACR 2017 - Day 2 Highlights
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated.
Read Article
CRIB Study Shows No Transplacental Transfer of Certolizumab
Mariette and colleagues have reported on the prospective pharmacokinetic study of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants at the time of birith.
Read Article
Does Birth Control or Breastfeeding Reduce RA Risk?
Researchers have reported their case-control study using the Swedish Epidemiological Investigation of RA study (2641 cases/4251 controls) to examine the influence of oral contraceptive (OC) use or breastfeeding on the risk of rheumatoid arthritis (RA).
Read Article
The RheumNow Week in Review - 20 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.
Read Article
BSR Guidelines on Lupus Management
In the UK, NICE has accredited the British Society of Rheumatology (BSR) to develop a guidance document on the management of systemic lupus erythematosus in adults. The last published guidelines for lupus were published in 2008 by EULAR and in 2012 by the ACR.
Read Article
The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read Article
Patterns of Biologic Use During Autoimmune Pregnancy
While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.
Read Article
Increasing Deaths and Breaking Bad with Fentanyl
Opioid overdose deaths quadrupled from 1999 to 2015 and accounted for 63% of drug overdose deaths in the United States in 2015. During 2010–2015, heroin overdose deaths quadrupled from 3,036 to 12,989, with heroin and illicitly manufactured fentanyl (IMF) as likely contributors to this trend.
Read Article
The RheumNow Week in Review – 4 August 2017
Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.
Read Article
No Increase in Malformations with Etanercept Use During Pregnancy
While there are several reports detailing uncontrolled, observational results of biologic use during pregnancy, most are hampered by low numbers, incomplete data and too small a sample to make reliable judgements regarding the teratogenicity. A company sponsored claims data analysis has shown that etanercept exposure during pregnancy was not associated with an increase in major congenital malformations (MCMs).
Read ArticleThe RheumNow Week in Review – 21 July 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com:
Read Article
Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too
A population-based claim study from Sweden has shown that lupus and pre-lupus patients are at risk for adverse maternal and fetal outcomes.
Read Article
FDA Approves Tremfya (guselkumab) for Plaque Psoriasis
The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.
Read Article
Breastfeeding Rates Lower in Lupus
It is a common practice for rheumatologists to discuss medication-related teratogenicity and disease implications in case of pregnancy. Yet, discussion of breastfeeding are often omitted.
Read Article
